Case Presentation. Case Presentation (continued) PHYSICAL EXAMINATION. 60 year old college professor dyspnea with exertion dry cough, throat clearing
|
|
- Benjamin Walton
- 6 years ago
- Views:
Transcription
1 Primary Care Medicine: Concepts and Controversies Thursday, February 18, 21 Fiesta Americana Puerto Vallarta, Mexico Interstitial Lung Disease: A Clinician s Approach to Diagnosis and Management Talmadge E. King, Jr., M.D. Krevins Distinguished Professor of Medicine Chair, Department of Medicine University of California San Francisco (UCSF) San Francisco, CA Case Presentation 6 year old college professor dyspnea with exertion dry cough, throat clearing Occupational/Environmental Exposures: shipyard worker (in his 2 s) home remodeled (within last 5 yrs.) Case Presentation (continued) PAST MEDICAL HISTORY: former smoker (2 pack-yrs; quit 1 yrs) coronary artery disease systemic arterial hypertension chronic nasal congestion GERD FAMILY & SOCIAL HISTORY Negative for lung disease MEDICATIONS: lisinopril (ACE inhibitor) lortadine (antihistamine) omeprazole (proton pump inhibitor) albuterol/ atrovent Case Presentation (continued) PHYSICAL EXAMINATION RR 14 Bibasilar crackles O 2 sat 98% at rest 9% after walking 2 meters 1
2 Case Presentation (continued) HRCT Scan of Lungs Baseline 1 yr 2 yr FEV1 2.8 (87) 2.7 (86) 2.5 (8) FVC 3.2 (72) 3.2 (72) 3. (68) FEV1/FVC 87% 85% 84% TLC 4. (59) 4.1 (61) 3.4 (5) DLCO 16.1 (6) 16.6 (62) 13.5 (51) Questions What is the diagnosis? Are additional studies needed to determine diagnosis? What is the prognosis? What treatment should be instituted? Diffuse Parenchymal Lung Diseases or Interstitial Lung Diseases (ILD) Heterogeneous group of noninfectious, nonmalignant processes of the lower respiratory tract (interstitial pneumonias) that commonly result Symptoms: dyspnea and cough Signs: crackles on chest exam; (clubbing) PFTs: restrictive ventilatory impairment Chest imaging: diffuse interstitial opacities Lung biopsy: granulomatous or interstitial inflammation and fibrosis Outcome: often progressive and often fatal 2
3 Lung Fibrosis Follows Many Different Forms of Lung Injury What are the Causes of ILD? Granulomatous reaction Drugs (chemotherapy) Radiation Inorganic dusts (asbestos, fumes, gases) Collagen vascular diseases Pulmonary hemorrhage syndromes (vasculitides) Lymphocytic infiltrative disorders Eosinophilic pneumonias Idiopathic interstitial pneumonias (UIP, DIP, NSIP, BOOP) Inherited diseases (tuberous sclerosis, familial PF) Endstage Fibrosis ( Honeycomb lung ) Major Histopathological Patterns Granulomatous Processes Granulomatous Reaction Inflammatory and fibrotic Sarcoidosis Organic dusts Hypersensitivity pneumonitis Inorganic dusts beryllium silica Granulomatous vasculitides Wegener s granulomatosis Churg-Strauss 3
4 Interstitial Inflammation and Fibrosis Diffuse Parenchymal Lung Diseases Idiopathic interstitial pneumonias (UIP, DIP, NSIP, OP, DAD, LIP) Collagen vascular diseases Inorganic dusts (asbestos, fumes, gases) Drugs (chemotherapy) Radiation Pulmonary hemorrhage syndromes Lymphocytic infiltrative disorders Eosinophilic pneumonias Inherited diseases (tuberous sclerosis) Other Systemic Disorders Occupational and Environmental Exposures Idiopathic Interstitial Pneumonias Connective Tissue Diseases Drug-Induced Lung Injury These conditions are uncommon and few physicians have substantial experience with their diagnosis and management. How Common is ILD? Diagnosis Prevalence Incidence Men Women Men Women Pulmonary fibrosis Occupational and environmental Connective tissue diseases Sarcoidosis Drug and radiation Pulmonary hemorrhage syndromes Other Total Coultas et al. Am.J.Respir.Crit.Care Med. 1994; 15:
5 Clinical Manifestations and Approach to the Diagnosis of ILD Approach to the Diagnosis of ILD: It Often Takes A Village! Clinical History Physical Laboratory PFTs Radiology Chest X-ray HRCT Pathology Surgical lung biopsy Primary Care Pulmonologists Radiologists Pathologists Multidimensional and multidisciplinary ATS/ERS Consensus Statement. Am J Respir Crit Care Med. 22;165: Clinical Presentations of DPLD Most common: DOE, cough, abnormal CXR, physiological impairment. Some: symptoms/signs, normal CXR & PFTs. (HRCT, BAL or exercise usually abnormal) Rarely, asymptomatic with abnormal CXR or physiological impairment (abnormal spirometry or low DLCO) Associated with another disease, esp, CTD Positive exposure history ILD Presentation: Symptoms and Signs Breathlessness (dyspnea) during or after physical activity Spasmodic, dry cough Gradual, unintended weight loss Fatigue or malaise Rapid shallow breathing Crackles on chest examination Clubbing, or enlargement of the ends of the fingers (or sometimes the toes) 5
6 PATIENT WITH SUSPECTED DPLD PATIENT WITH SUSPECTED DPLD Age Duration of illness Family history Exposures (patient & spouse, at work, home, hobbies) Drugs Careful History & Physical Exam Rapid shallow breathing Crackles on chest examination Clubbing Pulmonary Function Testing Chest X-ray and CT Scans Bronchoscopy (TBBx) Bronchoalveolar Lavage Open Lung Biopsy Exercise Testing Careful History & Physical Exam Routine Studies PFTs = Restrictive Impairment Measurements of Gas Exchange Expiratory flow (l/s) Flow is increased at all lung volumes IPF Pred Volume (Liters from TLC) Elastic recoil is increased Emphysema TLC (% PRED) 1 5 Normal range IPF Transpulmonary Pressure (cm H 2 O) Hypoxemia worsens Excessive ventilatory and heart rate response Correlates with disease severity Exercise Testing Predicted max VO 2 (%) 6
7 Hx and HRCT confident for IPF STOP UIP Approach to the ILD Patient Patient with Suspected ILD Hx and HRCT Dx of other ILD NSIP STOP Hx, PE, CXR, PFT, Labs RBILD HRCT Atypical clinical or CT features of IPF No DIP VATS DAD Yes - OP Not IIP (e.g. associated collagen vascular disease, environmental, drugrelated, etc.) Suspected other ILD Dx likely by bronch? LIP STOP Is bronch diagnostic? + STOP Non IIP Importance of Early Diagnosis of ILD Provide an explanation of the patients symptoms Identify treatable diseases Allow early initiation of treatment Allow for earlier referral and enrollment in clinical trials Generally limited to patients with mild to moderate disease Begin evaluation for lung transplant earlier Diffuse Parenchymal Lung Diseases Drug-Induced Lung Injury Drug-induced Lung Disease Common but NOT easy to prove Clinical-radiologic-pathologic pattern unreliable Diagnosis of exclusion (vs. infection, heart failure) Occurs usually during the treatment or shortly after the drug is withdrawn Can have long latent period (months to years, e.g., carmustine) 7
8 Diffuse Parenchymal Lung Diseases Occupational and Environmental Exposures Occupational and Environmental Exposures Occupational and Environmental Exposures Inorganic dusts asbestosis silicosis Organic dusts Fungal spores Animal proteins Gases, fumes, vapors, aerosols 8
9 Hypersensitivity Pneumonitis (Extrinsic Allergic Alveolitis) NOT a single, uniform disease Complex syndrome of varying: clinical presentation intensity natural history An immunologic reaction to an inhaled agent, particularly an organic antigen. King, TE, Jr. UpToDate EPIDEMIOLOGY Largely unknown. Few population-based studies Prevalence and incidence vary considerably depending upon case definitions intensity of exposure to inciting antigens season geographical conditions local practices and customs proximity to certain industries host risk factors King, TE, Jr. UpToDate Prevalence - Farmer's lung Number of cases in the population at risk at a given time Affects.4 to 7 percent of the farming population Varies by Region and climate farming practices ~ 9% at risk in humid zones to 2% in drier zones United States 42 to 3 (per 1,) United Kingdom 12 to 23 France 437 King, TE, Jr. UpToDate Incidence - Farmer's lung Number of new cases in the population at risk in a given year 8 to 54 per 1, per year Varies considerably and is influenced by several factors. In Finland, significant variation according to season Most cases occur in April near the end of the indoor feeding season for cattle Lowest in October, when outdoor feeding is norm. The incidence correlates positively with the King, TE, Jr. UpToDate 9
10 Prevalence -- Bird Fanciers Prevalence -- Bird Fanciers Highly variable 2 to 2, per 1, persons at risk Likely higher among bird fanciers than among farmers because contact with antigens is more prolonged Species of birds and the handling practices employed may affect prevalence Pigeon breeders: 6, to 21, per 1, per year (6 to 21 percent per year) King, TE, Jr. UpToDate King, TE, Jr. UpToDate Incidence Other Exposures High attack rates during sporadic outbreaks 52% office workers with humidifier lung (Ganier M, et al. Chest 198; 77:183) 37% lifeguards at public swimming pool (Rose CS, et al. Am J Public Health 1998; 88:795) 27% workers at an injection molding plant manufacturing polyurethane foam parts for automobiles (Simpson C, et al. Am J Ind Med 1996; 3:48) 15% office workers with contaminated forced air system (Banaszak EF, N Engl J Med 197; 283:271) King, TE, Jr. UpToDate ETIOLOGIC AGENTS Wide range of occupations and avocations Over 3 etiologies reported. Some are single or small number of cases and require further study. King, TE, Jr. UpToDate 1
11 Ceiling Tiles in Office of Owner Water on the Roof Damage To HVAC Unit 11
12 Swimming Pool and Water Units Hot Tub Lung Mycobacterium-avium Complex CHEST 1997; 111: Treatment Modify or avoid the culprit environment in order to minimize ongoing exposure. Corticosteroid treatment with.5 to 1. mg of prednisone per kg of ideal body weight per day (up to 6 mg/day) should be considered for severely symptomatic patients. The initial dose is maintained for one to two weeks and is then tapered over the next two to four weeks. Maintenance therapy is rarely required. Diffuse Parenchymal Lung Diseases Systemic Disorders King, TE, Jr. UpToDate 12
13 Other Systemic Diseases Sarcoidosis Vasculitides Wegener's granulomatosis Churg-Strauss syndrome Hemorrhagic syndromes Goodpasture's syndrome Pulmonary capillaritis Pulmonary Histiocytosis X Chronic gastric aspiration Lymphangitic carcinomatosis Alveolar proteinosis Chronic pulmonary edema Sarcoidosis: Definition A multisystem granulomatous disease of unknown cause(s) that primarily affects the lung and lymphatic systems of the body. Sven Löfgren: we cannot adequately define sarcoidosis because we do not know its etiology Sarcoidosis: Epidemiology Incidence (rate per 1,) Sarcoidosis: Epidemiology Estimated Prevalence/1, Number of new cases occurring during a given time, usually 1 yr. Lifetime risk for U.S. blacks is 2.4 percent, and that for U.S. whites.85 percent U.S. Blacks U.S. Whites Finland Great Britain Japan Blacks Puerto Ricans Hispanics Whites James, D.G. and Y. Hosoda, Epidemiology, in Sarcoidosis and other granulomatous disorders., D.G. James, Editor. 1994, Marcel Dekker, Inc.: New York. p
14 Sarcoidosis: Epidemiology Estimated Prevalence: Comparisons >5/1, Denmark: 53/1, Sweden: 55-64/1, 4-5/1, Germany: 43/1, 3-4/1, NYC: 39/1, 2-3/1, Norway: 27/1, Great Britain: 2/1, 1-2/1, Canada: ~1/1, France: 1/1, Under 1/1, Japan: <5/1, Australia: 8/1, Brazil: <3/1, Spain:.5/1, Sarcoidosis: Epidemiology Age at Presentation Seen at all ages Peak incidence: age Blacks are (?) younger No relation to clinical presentation, prognosis, or geographic location Scandinavian countries and Japan have a second peak incidence in women > 5 yr Neville E, Walker AN, James DG. Prognostic factors predicting outcome of sarcoidosis: analysis of 818 patients. QJMed 1983;52: Percent of cases (n = 818) Age at Onset CRITERIA FOR DIAGNOSIS Compatible clinical illness Histologic confirmation Exclusion of other illnesses Sarcoidosis: Initial Evaluation Exclude Critical Organ Involvement Determine Extent and Severity of Disease Exclude Other Diseases Thomas KW, Hunninghake GW: Sarcoidosis. JAMA 23; 289(24):
15 Sarcoidosis: Initial Evaluation Exclude Critical Organ Involvement Complete neurological examination Electrocardiogram Complete ophthalmologic examination Sarcoidosis: Initial Evaluation Determine Extent and Severity of Disease Chest radiographs Pulmonary function testing: spirometry, DLCO Hepatic enzyme measurements Renal assessments: electrolyte, blood urea nitrogen, creatinine levels Urine analysis Complete blood cell count Serum calcium levels Thomas KW, Hunninghake GW: Sarcoidosis. JAMA 23; 289(24): Thomas KW, Hunninghake GW: Sarcoidosis. JAMA 23; 289(24): Sarcoidosis: Initial Evaluation Exclude Other Diseases Occupational and environmental exposure history Tuberculin skin test What are the signs and symptoms of sarcoidosis? Thomas KW, Hunninghake GW: Sarcoidosis. JAMA 23; 289(24):
16 Symptoms at Presentation 4 to 6% are asymptomatic Commonly discovered on routine chest x-ray 1 to 15% begin acutely with Lofgren s syndrome 9% have intrathoracic disease Chest x-ray useful anatomical guide for lung involvement, cannot be used to: Stage activity of disease Assess functional defects SARCOIDOSIS Lofgren s Syndrome Acute presentation o Women, esp. Swedish, Irish, Puerto Rican o Erythema nodosum o Acute arthralgia o Bilateral hilar lymphadenopathy Only 1-28% of cases at presentation Invariably improves within 1 to 2 yrs. SARCOIDOSIS: Lofgren s Syndrome Radiographic Stages of Sarcoidosis Classification is based on the PA chest radiogram only. Sometimes the CT scan or 67Ga lung scan gives information suggesting a different stage Hunninghake GW, Costabel U, Ando M, et al. ATS Statement on sarcoidosis. AMJ Respir Crit Care Med. 1999;16:
17 Estimated Frequency of Extrathoracic Involvement Peripheral lymph nodes 73% Skin 32% Liver 21% Eye 21% Spleen 18% Bone 14% Treatment of Sarcoidosis Corticosteroids Cytotoxic Agents Methotrexate Azathioprine. Cyclophosphamide Chlorambucil Other Agents Hydroxychloroquine (Chloroquine) Ketoconazole Infliximab Absolute and Relative Indications for Corticosteroids Diffuse Parenchymal Lung Diseases Absolute Ocular Myocardial Central Nervous System Relative Hypercalcemia Skin Lesions Connective Tissue Disorders 17
18 Systemic Sclerosis Polymyositis-Dermatomyositis Pulmonary Manifestations CTD Rheumatoid Arthritis ILD complicating CTDs accounts for ~ 25 percent of all ILD mortality and 2 percent of all respiratory deaths in U.S.A. Usually the CTD is clinically evident. CTDs affect all areas of the lung, i.e., the airways, alveoli, vascular system and pleura, and does so in various degrees and combinations Pulmonary Manifestations CTDs Often the ILD is mild, but may be progressive and dominate the clinical picture Pathogenesis unclear but thought to be part of the systemic process. Diffuse Parenchymal Lung Diseases Idiopathic Interstitial Pneumonias 18
19 Diffuse Parenchymal Lung Diseases Idiopathic Pulmonary Fibrosis (UIP) Idiopathic interstitial pneumonias How Common Are the Different Histopathological Patterns of IIP? HISTOPATHOLOGICAL SUBGROUPS Relative Frequency SURVIVAL FOR UIP vs. NSIP 1 1 UIP = 47-62% NSIP = 14-36% DIP/RBILD = 1-17% AIP = 2% Other = 12-26% % Alive NSIP UIP Others NSIP UIP * other = bronchiolitis (4), BOOP (4), CEP (1), HSP (1), honeycomb changes only (1), hemorrhage (1), scarring/pneumonia (1) Years Daniil ZD et al. Am J Respir Crit Care Med. 1999;16:899. Years Bjoraker JA et al. Am J Respir Crit Care Med. 1998;157:
20 Idiopathic Pulmonary Fibrosis Overview - IPF Onset: Usually between 5 and 7 years Clinical presentation Males, current or former smokers Progressive dyspnea on exertion Paroxysmal cough, usually non-productive Abnormal breath sounds on chest auscultation Abnormal chest x-ray or HRCT Restrictive pulmonary physiology with reduced lung volumes and DLCO, and widened AaPO2 Epidemiology of IPF Incidence 1.7 cases per 1, per year for males 7.4 cases per 1, per year for females. 6.8 and 16.3 per 1, pe Prevalence (approximately 35,-55, cases) 2 cases per 1, for males 13 cases per 1, for females. Nationwide prevalence of IPF in Finland (as defined by the new ATS/ERS criteria) was estimated to be 16 to 18 per 1,. Incidence and prevalence of IPF increases markedly with age Per Hundred Thousand Incidence Male Female Estimated 31, New Patients per Year in the United States Estimated 83, Current Patients in the United States Weycker D, et al. Prevalence, Incidence, and Economic Costs of Idiopathic Pulmonary Fibrosis. Paper presented at: CHEST 22 San Diego, CA. Per Hundred Thousand Prevalence Male Female
21 IPF/UIP: Radiographic Findings HRCT Pattern Consistent With UIP-IPF Pattern Chest Radiograph HRCT Bibasilar, peripheral reticular opacities ( ± traction bronchiectasis) Lower lobe honeycombing Irregular lines in the upper lobes. One present: sensitivity = 91%, specificity = 64%, positive predictive value =79%, negative predictive value = 82% Both present: sensitivity = 74%, specificity = 81%, positive predictive value = 85%, negative predictive value = 67%. Absence of alveolar opacities, peribronchovascular nodules, micronodules, mediastinal adenopathy Chest. 23;124: Idiopathic Pulmonary Fibrosis Usual Interstitial Pneumonia Healthy Lung Idiopathic Pulmonary Fibrosis Peripheral acinar distribution Subpleural and adjacent to the septa and bronchovascular bundles Fibroblastic foci = organizing acute lung injury and sites of active collagen synthesis in a badly distorted lung 21
22 No Effective Treatment for IPF/UIP and Survival Rate is Very Poor 1 1 IPF/UIP Natural history % Alive UIP UIP Years Years Daniil ZD et al. Am J Respir Crit Care Med. 1999;16:899. Bjoraker JA et al. Am J Respir Crit Care Med. 1998;157:199. IPF: As bad as lung cancer! Disease 5-year survival (%) Lung cancer 14 IPF-UIP 2-3 CHF <5 Colorectal cancer 62 Median survival of patients with biopsy-proven IPF is less than 3 years after diagnosis (n = 238) Median survival from onset of symptoms = 8.8 mo; 95% CI: Median survival from diagnosis = 35.2 mo; 95% CI: Breast cancer 86 Prostate cancer 9 King TE Jr, et al Am J Respir Crit Care Med 21; 164:
23 Forced vital capacity (FVC) declines ~2 ml per year Slow decline, rapidly progressive vs acute exacerbation.5 Baseline Pirfenidone= Slowly progressive Respiratory function/symptoms Acute exacerbations Rapidly progressive IFNγ = Etanercept= -.2 Bosentan = Time (weeks) >5 Years // NAC = -.19 Placebo Percent alive Change from baseline (liters).1 In IPF there are several patterns of progression (5-year survival = 2-3%) 6 Radiographic Changes of Acute Exacerbation Smoking status has profound impact on the disease pattern and clinical course Pathologic Changes of Acute Exacerbation UIP Progressive bilateral shadowing of lung parenchyma Do not usually resolve, even after treatment OP DAD Ambrosini, V., A. Cancellieri, M. Chilosi, M. Zompatori, R. Trisolini, L. Saragoni, and V. Poletti. 23. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 22(5):
24 Where we re going Anti-inflammatory Immunomodulation Anti-fibrotic IPF: Treatment Immunosuppression Corticosteroids Colchicine D-penicillamine Azathioprine Cyclophosphamide Anti-oxidant NAC Glutathione IFN-γ 1b Etanercept Pirfenidone Imatinib Bosentan Anti-proliferative FG-319? GC-18? Statins? LO Inhibitors? Combo Tx? 195s 199s 29 Future Thank you for your attention. 24
Case Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco
Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary
More information4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More informationA Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco
A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Why it is important Definition/Classification
More informationA Review of Interstitial Lung Diseases
Outline A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Overview of diagnosis in ILD Why it is important Definition/Classification
More informationINTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
More informationInternational consensus statement on idiopathic pulmonary fibrosis
Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic
More informationOutline Definition of Terms: Lexicon. Traction Bronchiectasis
HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of
More information5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +
More information11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment
More informationFinancial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature
Financial disclosure I have no financial relationships to disclose. Douglas Johnson D.O. Cardiothoracic Imaging Gaston Radiology COMMON DIAGNOSES IN HRCT High Res Chest Anatomy Nomenclature HRCT Sampling
More informationINTERSTITIAL LUNG DISEASE Dr. Zulqarnain Ashraf
Indep Rev Jul-Dec 2018;20(7-12) Dr. Zulqarnain Ashraf IR-653 Abstract: ILD is a group of diseases affect interstitium of the lung. Repeated insult to the lung cause the interstitium to be damaged. Similarly
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationLiebow and Carrington's original classification of IIP
Liebow and Carrington's original classification of IIP-- 1969 Eric J. Stern MD University of Washington UIP Usual interstitial pneumonia DIP Desquamative interstitial pneumonia BIP Bronchiolitis obliterans
More informationLines and crackles. Making sense of ILD
Lines and crackles Making sense of ILD Case JM 65 year old male Gradual shortness of breath, going on over a year Some dry cough Ex-smoker, quit 10 years ago Crackles in the bases CXR presented Sent to
More informationManish Powari Regional Training Day 10/12/2014
Manish Powari Regional Training Day 10/12/2014 Large number of different types of Interstitial Lung Disease (ILD). Most are very rare Most patients present with one of a smaller number of commoner diseases
More informationCLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD)
CLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD) David Northrop MBA, RRT Assistant Director of Respiratory Therapy Services The University of Kansas Health System Clinical Assistant
More informationCTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
More informationNew Horizons The Future of IPF and ILD
New Horizons The Future of IPF and ILD Talmadge E. King, Jr., M.D. Julius R. Krevans Distinguished Professorship in Internal Medicine Chair, Department of Medicine University of California San Francisco
More informationInterstitial Lung Disease ILD: Definition
Interstitial Lung Disease 2007 Paul F. Simonelli,, MD, PhD, FCCP Clinical Director Center for Interstitial Lung Disease Columbia University Medical Center 1. ILD is not one disorder ILD: Definition 2.
More informationOverview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe
More informationDiffuse Interstitial Lung Diseases: Is There Really Anything New?
: Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There
More informationEpidemiology and classification of smoking related interstitial lung diseases
Epidemiology and classification of smoking related interstitial lung diseases Šterclová M. Department of Respiratory Diseases, Thomayer Hospital, Prague, Czech Republic Supported by an IGA Grant No G 1207
More informationDiagnostic challenges in IPF
Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from
More informationDisclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None
Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona
More informationDiagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines
Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Rebecca Keith, MD Assistant Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO Objectives
More informationUpdate on Therapies for Idiopathic Pulmonary Fibrosis. Outline
Update on Therapies for Idiopathic Pulmonary Fibrosis Paul Wolters Associate Professor University of California, San Francisco Outline Classification of Interstitial lung disease Clinical classification
More informationPathologic Assessment of Interstitial Lung Disease
Pathologic Assessment of Interstitial Lung Disease Dry and itchy? It could be eczema or fungal infection. We don t need to worry, the drugs aren t that dangerous. Kirk D. Jones, MD UCSF Dept. of Pathology
More informationDifferential diagnosis
Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential
More informationDefinition, classification and epidemiology
Interstitial Lung Diseases Definition, classification and epidemiology Haluk Türktaş Professor of Pulmonary Medicine Gazi University Ankara Interstitial Lung Diseases Definition of ILD A diverse group
More informationInterstitial Lung Diseases(ILD) By : Dr. Shaher M. Samrah Done by : Ibrahim M. sun
Interstitial Lung Diseases(ILD) By : Dr. Shaher M. Samrah Done by : Ibrahim M. sun. 26.11.11 Introduction Interstitial Lung Diseases (ILD) are group of diseases that affect the interstitium of the lungs,
More informationDisclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:
Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the
More informationHypersensitivity Pneumonitis: Epidemiology and Classification
Hypersensitivity Pneumonitis: Epidemiology and Classification Ulrich Costabel, MD University of Duisburg-Essen, Ruhrlandklinik Department of Pneumology/Allergy Objectives Definitions, Etiology Epidemiology
More informationCase 4 History. 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar
Case 4 History 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar basilar infiltrates suggestive of pulmonary fibrosis Open
More informationTBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than
TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients
More informationUsual Interstitial pneumonia and Nonspecific Interstitial Pneumonia. Nitra and the Gangs.
Usual Interstitial pneumonia and Nonspecific Interstitial Pneumonia Nitra and the Gangs. บทน ำและบทท ๓, ๑๐, ๑๒, ๑๓, ๑๔, ๑๕, ๑๗ Usual Interstitial Pneumonia (UIP) Most common & basic pathologic pattern
More informationGuidelines for Diagnosis and Treatment of IPF
Guidelines for Diagnosis and Treatment of IPF Katerina Antoniou, MD, PhD Lecturer in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Classification of Interstitial Lung Disease
More informationReplacement of air with fluid, inflammatory. cells or cellular debris. Parenchymal, Interstitial (Restrictive) and Vascular Diseases.
Parenchymal, Interstitial (Restrictive) and Vascular Diseases Alain C. Borczuk, M.D. Dept of Pathology Replacement of air with fluid, inflammatory cells Pulmonary Edema Pneumonia Hemorrhage Diffuse alveolar
More informationHYPERSENSITIVITY PNEUMONITIS
HYPERSENSITIVITY PNEUMONITIS A preventable fibrosis MOSAVIR ANSARIE MB., FCCP INTERSTITIAL LUNG DISEASES A heterogeneous group of non infectious, non malignant diffuse parenchymal disorders of the lower
More informationNONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP
UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF () FOR PATHOLOGISTS Thomas V. Colby, M.D. Professor of Pathology (Emeritus) Mayo Clinic Arizona FINANCIAL DISCLOSURES NONE OVERVIEW IPF Radiologic Dx Pathologic
More informationDiagnosing ILD. What is important in 2016? Chris Grainge
Diagnosing ILD What is important in 2016? Chris Grainge Senior Staff Specialist Respiratory Medicine John Hunter Hospital Conjoint A/Prof University of Newcastle Conflict of interest I have acted as a
More informationUnpaid scientific collaborator & advisor with Veracyte, Inc.
Diagnosis and Classification of Idiopathic Interstitial Pneumonias: Role of Histopathology in the Golden Age of Consensus Jeffrey L. Myers, M.D. A. James French Professor of Diagnostic Pathology Vice Chair
More informationUIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION!
UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION! STÉPHANE JOUNEAU 11 JULY 2014 Respiratory Medicine Department, Pontchaillou Hospital, Rennes, France CASE OVERVIEW This case highlights how a usual
More informationPNEUMOCONIOSES DIAGNOSIS, DIFFERENTIAL DIAGNOSIS AND TREATMENT. Carlos Robalo Cordeiro
PNEUMOCONIOSES DIAGNOSIS, DIFFERENTIAL DIAGNOSIS AND TREATMENT Carlos Robalo Cordeiro carlos.crobalo@gmail.com Diagnosis 1 History of sufficient exposure to dust, in time and intensity/either occupational
More informationProgress in Idiopathic Pulmonary Fibrosis
Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim
More informationNew Therapies and Trials in IPF
Conflict of interest disclosure I have the following real or perceived conflicts of interest that relate to this presentation: New Therapies and Trials in IPF Talmadge E. King, Jr., M.D. Julius R. Krevans
More informationNon-neoplastic Lung Disease II
Pathobasic Non-neoplastic Lung Disease II Spasenija Savic Prince Pathology Program Systematic approach to surgical lung biopsies with ILD Examples (chronic ILD): Idiopathic interstitial pneumonias: UIP,
More informationBronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy
Idiopathic Pulmonary Fibrosis Bronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy JMAJ 46(11): 469 474, 2003 Yukihiko SUGIYAMA Professor, Division of Pulmonary Medicine, Department of
More informationCase 1 : Question. 1.1 What is the intralobular distribution? 1. Centrilobular 2. Perilymphatic 3. Random
Interesting case Case 1 Case 1 : Question 1.1 What is the intralobular distribution? 1. Centrilobular 2. Perilymphatic 3. Random Case 1: Answer 1.1 What is the intralobular distribution? 1. Centrilobular
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Idiopathic Pulmonary Fibrosis Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Idiopathic Pulmonary Fibrosis (Esbriet /pirfenidone, Ofev /nintedanib)
More information* * APPROACH TO NON- NEOPLASTIC LUNG DISEASE IN TRANSBRONCHIAL AND SURGICAL BIOPSIES. Financial Disclosures: NONE. BIOPSY TECHNIQUES Bronchoscopic
APPROACH TO NON- NEOPLASTIC LUNG DISEASE IN TRANSBRONCHIAL AND SURGICAL BIOPSIES Thomas V. Colby, M.D. Mayo Clinic Arizona Geraldine C. Zeiler Professor of Cytopathology Mayo Clinic Arizona Financial Disclosures:
More informationIdiopathic Pulmonary Fibrosis Treatable and Not Idiopathic
Idiopathic Pulmonary Fibrosis Treatable and Not Idiopathic Brett Ley, MD University of California San Francisco CTS 1/26/18 Disclosures Speaker s bureau honorarium from Genentech (makers of pirfenidone)
More informationKaterina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Prague, June 2014
Hypersensitivity pneumonitis: Causes, clinical course, diagnosis and differential diagnosis, treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationA case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel
A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical
More informationInterstitial Lung Disease
Interstitial Lung Disease Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring (i.e. fibrosis ) and/or inflammation
More informationIPF: Epidemiologia e stato dell arte
IPF: Epidemiologia e stato dell arte Clinical Classification Diffuse parenchimal lung diseases Exposure-related: - occupational - environmental - medication Desquamative interstitial pneumonia Idiopathic
More informationIdiopathic Pulmonary of Care
Chapter 6.1 Living Medical etextbook A Digital Tool at the Point of Care From Projects In Knowledge Pulmonology Idiopathic Pulmonary Fibrosis @Point of Care IPF Case Study: Typical Presentation, Role of
More informationHypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas
Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Rishi Raj MD Director, Interstitial Lung Diseases Program Clinical Professor of Pulmonary and Critical Care Medicine Stanford University
More informationI have no relevant conflicts of interest to disclose
I have no relevant conflicts of interest to disclose Diffuse parenchymal lung disease (DPLD) and its associations Secondary lobular anatomy DPLD History, clinical findings, temporal evolution, and exposures
More informationParenchymal, Interstitial i (Restrictive) i and Vascular Diseases
Pulmonary Diseases: Structure-Function Correlation II Parenchymal, Interstitial i (Restrictive) i and Vascular Diseases Alain C. Borczuk, M.D. Dept of Pathology Pulmonary Diseases: Structure-Function Correlation
More informationDIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
More informationAcute and Chronic Lung Disease
KATHOLIEKE UNIVERSITEIT LEUVEN Faculty of Medicine Acute and Chronic Lung Disease W De Wever, JA Verschakelen Department of Radiology, University Hospitals Leuven, Belgium Clinical utility of HRCT To detect
More informationINTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)
INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) Marilyn K. Glassberg Csete, M.D. Professor of Medicine, Surgery, and Pediatrics Director, Interstitial and Rare Lung Disease Program
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationDr.kassim.m.sultan F.R.C.P
Dr.kassim.m.sultan F.R.C.P inflammatory disorder of the lung, involving alveolar walls and terminal airways, that is induced, in a susceptible host, by repeated inhalation of a variety of organic agents.
More informationTimely Topics in Pulmonary Medicine
Disclosures Timely Topics in Pulmonary Medicine I have nothing to disclose! Lorriana Leard, MD Associate Professor of Clinical Medicine Chief of Clinical Operations UCSF Pulmonary, Critical Care, Allergy
More informationCase 1: Question. 1.1 What is the main pattern of this HRCT? 1. Intralobular line 2. Groundglass opacity 3. Perilymphatic nodule
HRCT WORK SHOP Case 1 Case 1: Question 1.1 What is the main pattern of this HRCT? 1. Intralobular line 2. Groundglass opacity 3. Perilymphatic nodule Case 1: Question 1.2 What is the diagnosis? 1. Hypersensitivity
More informationChest imaging II. Interstitial lung diseases
Chest imaging II. Interstitial lung diseases Dávid L. Tárnoki MD, PhD Ádám D. TárnokiMD, PhD Department of Radiology Semmelweis University Topics 1. Interstitial lung diseases 2. Occupational lung diseases
More informationChallenges in the Diagnosis of Interstitial Lung Disease
Challenges in the Diagnosis of Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept. of Pathology kirk.jones@ucsf.edu Overview New Classification of IIP Prior classification Modifications for new classification
More informationCase 1. Case Presentation. Disclosure Statement. ILD: What the generalist needs to know
Disclosure Statement Interstitial Lung Disease: What the Generalist Needs to Know A Case Based Approach Talmadge E. King, Jr., M.D. Julius R. Krevans Distinguished Professorship in Internal Medicine Chair,
More informationControversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)
Controversies in Clinical Trials Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies to be highlighted by IPF Post-hoc analyses Story Primary end point selection Changing prespecified endpoints
More informationHistopathologic Approach to Interstitial Lung Disease
Histopathologic Approach to Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept of Pathology kirk.jones@ucsf.edu Disclosures I have nothing to disclose 1 Why? Much of interstitial lung disease biopsies
More informationSarcoidosis Registry Proforma
Patient Demographics Patient Data Has a patient consent form been completed? 1.1 Title Mr 1.2 1.3 Forename(s) PlainText Surname PlainText 1.4 Gender Male 1.5 1.6 1.7 1.8 1.9 Mrs Ms Miss Dr Other
More informationSCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW
SCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW Lung disease can be a serious complication of scleroderma. The two most common types of lung disease in patients with scleroderma are interstitial
More informationSystemic lupus erythematosus (SLE): Pleuropulmonary Manifestations
08/30/10 09/26/10 Systemic lupus erythematosus (SLE): Pleuropulmonary Manifestations Camila Downey S. Universidad de Chile, School of Medicine, Year VII Harvard University, School of Medicine Sept 17,
More informationThe radiological differential diagnosis of the UIP pattern
5th International Conference on Idiopathic Pulmonary Fibrosis, Modena, 2015, June 12th The radiological differential diagnosis of the UIP pattern Simon Walsh King s College Hospital Foundation Trust London,
More informationPatient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens
Patient with FVC>90% predicted Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 63-year-old, male patient with progressive exertional dyspnoea lasting for 2 years and dry cough
More informationMultidisciplinary Diagnosis in Action: Challenging Case Presentations
Multidisciplinary Diagnosis in Action: Challenging Case Presentations Interstitial Lung Disease: Advances in Diagnosis and Management UCSF CME November 8, 2014 Case 1 69 yo M 3 year history of intermittent
More informationIPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?
IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K.
More informationDIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY?
NIHR Southampton Respiratory Biomedical Research Unit DIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY? Fibrosing Interstitial Lung Diseases CPFS/WASOG/AIPO/ERS
More informationBronkhorst colloquium Interstitiële longziekten. Katrien Grünberg, klinisch patholoog
Bronkhorst colloquium 2013-2014 Interstitiële longziekten De pathologie achter de CT Katrien Grünberg, klinisch patholoog K.grunberg@vumc.nl Preparing: introduction and 3 cases The introduction on microscopic
More informationERS 2016 Congress Highlights Interstitial Lung Disease (ILD)
ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the
More informationCareful histopathological evaluation has shown the traditionally clinical diagnosis of
Demystifying Idiopathic Interstitial Pneumonia Harold R. Collard, MD; Talmadge E. King, Jr, MD REVIEW ARTICLE Careful histopathological evaluation has shown the traditionally clinical diagnosis of idiopathic
More informationCASE OF THE MONTH. Lung Disease in Rheumatoid Arthritis
CASE OF THE MONTH Lung Disease in Rheumatoid Arthritis 61 year old male Maōri Height: 174 cm Weight: 104.6kg BMI: 34.55 Problems 1. Rheumatoid related interstitial lung disease with UIP pattern 2. Secondary
More informationInterstitial Lung Disease (ILD)
Interstitial Lung Disease (ILD) ILD comprises more than 130 distinct disorders Characterized by cellular proliferation, cellular infiltration, and/or fibrosis of the lung parenchyma not due to infection
More informationChallenges in the Diagnosis of Interstitial Lung Disease
Challenges in the Diagnosis of Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept. of Pathology kirk.jones@ucsf.edu Overview New Classification of IIP Prior classification Modifications for new classification
More informationIPF - Inquadramento clinico
IPF - Inquadramento clinico Sergio Harari Unità Operativa di Pneumologia UTIR Servizio di Fisiopat. Resp. e Emodinamica Polmonare Ospedale S. Giuseppe, Milano Clinical Classification Diffuse parenchimal
More informationDéjà vu all over again
Disclosures Déjà vu all over again None Jonathan Singer MD MS University of California, San Francisco HPI 49 y/o woman presents for lung transplant evaluation for Hypersensitivity Pneumonitis Exposures:
More informationC h a p t e r 1 3 Interstitial Lung Disease
C h a p t e r 1 3 Interstitial Lung Disease Shirish P Shah 1, Somesh Chaudhary 2, P Shetty 2 1 Consultant Chest Physician, Nanavati Hospital, Mumbai, Former Head of Department of Chest Medicine, BYL Nair
More informationPulmonary Function Testing The Basics of Interpretation
Pulmonary Function Testing The Basics of Interpretation Jennifer Hale, M.D. Valley Baptist Family Practice Residency Objectives Identify the components of PFTs Describe the indications Develop a stepwise
More informationPatient with IPF and no honeycombing on HRCT. Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens
Patient with IPF and no honeycombing on HRCT Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 76-year-old male patient presented with progressive exertional dyspnoea refractory
More informationDaria Manos RSNA 2016 RC 401. https://medicine.dal.ca/departments/depar tment-sites/radiology/contact/faculty/dariamanos.html
Daria Manos RSNA 2016 RC 401 https://medicine.dal.ca/departments/depar tment-sites/radiology/contact/faculty/dariamanos.html STEP1: Is this fibrotic lung disease? STEP 2: Is this a UIP pattern? If yes:
More informationInterstitial Lung Disease
Interstitial Lung Disease Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring (i.e. fibrosis ) and/or inflammation
More informationPulmonary Sarcoidosis - Radiological Evaluation
Original Research Article Pulmonary Sarcoidosis - Radiological Evaluation Jayesh Shah 1, Darshan Shah 2*, C. Raychaudhuri 3 1 Associate Professor, 2 1 st Year Resident, 3 Professor and HOD Radiology Department,
More informationCombined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases
CASE REPORT Combined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases Nobuhiko Nagata 1, Kentaro Watanabe 2, Michihiro Yoshimi 3, Hiroshi Okabayashi 4, Katsuo Sueishi 5, Kentaro
More informationHRCT in Diffuse Interstitial Lung Disease Steps in High Resolution CT Diagnosis. Where are the lymphatics? Anatomic distribution
Steps in High Resolution CT Diagnosis Pattern of abnormality Distribution of disease Associated findings Clinical history Tomás Franquet MD What is the diagnosis? Hospital de Sant Pau. Barcelona Secondary
More informationSummary of eligibility criteria for the Phase 3 multinational studies
SUPPLEMENTAL MATERIAL Table 1 Summary of eligibility criteria for the Phase 3 multinational studies CAPACITY (Studies 004 and 006) ASCEND (Study 016) Age 40 to 80 years Confident IPF diagnosis within the
More informationNintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis
Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis Brad Zimmermann, PharmD, MBA Pharmacy Grand Rounds May 02, 2017 Rochester, Minnesota 2017 MFMER slide-1 Objectives
More informationLUNG DISEASES DUE TO ORGANIC&INORGANIC DUSTS. Dr.kassim.m.sultan F.R.C.P
LUNG DISEASES DUE TO ORGANIC&INORGANIC DUSTS Dr.kassim.m.sultan F.R.C.P efinition of hypersensitivity pneumonitis(extrinsic allergic alveolitis): Inflammatory disorder of the lung, involving alveolar walls
More informationCOI: no conflicts of interest to declare
Idiopathic versus secondary Usual Interstitial Pneumonia (UIP) pattern in a series of 96 consecutive surgical lung biopsies: The value of histologic ancillary findings in a multidisciplinary discussion
More information